Alexandru Stieber/LinkedIn
Dec 18, 2025, 13:34
Alexandru Stieber Explores VEXAS Syndrome
Alexandru Stieber, Internal Medicine Resident at SUUMC Bucharest, shared on LinkedIn:
”Second set of scientific updates from the SNFMI Congress that took place last week in Tours, France.
The theme of today’s post revolves around VEXAS syndrome, new implications for patients with a VEXAS-like phenotype and the evolving concept of “clonal hematopoiesis of immunological significance” (CHIS).
- proven efficacy of azacitidine treatment in VEXAS patients, even in the absence of myelodysplastic syndrome
- proven pathophysiology of UBA1 mutated myeloid cells that drive an inflammatory millieu which alters normal hematopoiesis
- new links found between clonalhematopoiesis with IDH mutations and inflammatory manifestations (polymyalgia rheumatica and large-vessel vasculitis), with resolution under targeted inhibitors”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!
-
Dec 18, 2025, 12:12Niraj Sharma: Can We Really Stop Anticoagulation After AF Ablation?